Trial Profile
A Phase 1b Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed / Refractory or Untreated CLL/SLL/PLL
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Obinutuzumab; Rituximab; Venetoclax
- Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Acerta Pharma
- 12 Dec 2023 Results of pooled analysis from CL001 , CL003 , CL006, CL007 and CL309 , presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 29 Nov 2023 According to an AstraZeneca media release, analysis of 5 studies (CL-001, CL-003, CL-006, CL-007 & CL-309) showing acceptable safety outcomes based on rates of nonfatal and fatal ventricular arrhythmias and sudden death in patients with CLL will be presented at 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 9 to 12 December 2023.
- 16 Oct 2023 Planned End Date changed from 25 Aug 2026 to 6 Sep 2027.